Support HealthHIV

National Health Council IPAY 2028 Patient and Provider Toolkit

Overview of IPAY 2028, including an op-ed, written comments, and a communications toolkit.

Letter to the Centers for Medicare and Medicaid Services

Letter by HealthHIV, September 18, 2026.

Access Considerations for People Aging with HIV: IRA Negotiations and BIKTARVY®

The Centers for Medicare & Medicaid Services (CMS) recently selected 15 Medicare-covered drugs for the third cycle of Medicare drug price negotiation, known as IPAY 2028, under the Inflation Reduction Act (IRA).

BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), a widely used single-tablet HIV treatment regimen, is one of the selected drugs.

This fact sheet provides information and considerations on these negotiations.

Joint Statement and Public Comments on the Proposed Changes to Connecticut’s Medicaid Protected Drug Classes

ADAP Advocacy and HealthHIV issued the following joint statement in response to the proposed changes to services for People Living with HIV/AIDS (PLWHA) under Medicaid as set forth in the Connecticut Governor’s Health and Human Services budget recommendations.

CMS Town Hall Meeting on Biktarvy Price Negotiations: Comments by Joseph Cherabie

Comments provided by Joseph Cherabie, MD, MSc, HIV Medicine Association, Board of Directors, during the Centers for Medicare and Medicaid Services Town Hall Meeting on Biktarvy Price Negotiations, April 22, 2026.

CMS Town Hall Meeting on Biktarvy Price Negotiations: Comments by Kevin Herwig

Comments provided by Kevin Herwig, HIV+Hepatitis Policy Institute, during the Centers for Medicare and Medicaid Services Town Hall Meeting on Biktarvy Price Negotiations, April 22, 2026.